68Ga-AAZTA-093 PET/CT: First-in-human Study

This is a first-in-human study testing a new radioactive imaging agent called 68Ga-AAZTA-093 that targets a protein called PSMA (found on prostate cancer cells) to see how it compares to the standard PSMA imaging scan in detecting prostate cancer using a PET/CT scan. **You may be eligible if...** - You have been diagnosed with prostate cancer (treated or untreated) - You are able to have both the new imaging scan (68Ga-AAZTA-093) and a standard PSMA PET/CT scan within one week of each other - You are willing to sign informed consent **You may NOT be eligible if...** - You have a known allergy to PSMA - You have a medical condition that might significantly interfere with the study in your doctor's opinion Talk to your doctor to see if this trial is right for you.